{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:08:52Z","timestamp":1792512532290,"version":"4.5.0"},"reference-count":129,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2022,11,27]],"date-time":"2022-11-27T00:00:00Z","timestamp":1669507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Deanship of Scientific Research, Vice Presidency for Graduate Studies and Scientific Research, King Faisal University, Al-Ahsa, Saudi Arabia","award":["GRANT772"],"award-info":[{"award-number":["GRANT772"]}]},{"name":"Deanship of Scientific Research, Vice Presidency for Graduate Studies and Scientific Research, King Faisal University, Al-Ahsa, Saudi Arabia","award":["129173"],"award-info":[{"award-number":["129173"]}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation, South Africa","doi-asserted-by":"publisher","award":["GRANT772"],"award-info":[{"award-number":["GRANT772"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation, South Africa","doi-asserted-by":"publisher","award":["129173"],"award-info":[{"award-number":["129173"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Lung cancer is considered the most commonly diagnosed cancer and one of the leading causes of death globally. Despite the responses from small-cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) patients to conventional chemo- and radiotherapies, the current outcomes are not satisfactory. Recently, novel advances in DNA sequencing technologies have started to take off which have provided promising tools for studying different tumors for systematic mutation discovery. To date, a limited number of DDR inhibition trials have been conducted for the treatment of SCLC and NSCLC patients. However, strategies to test different DDR inhibitor combinations or to target multiple pathways are yet to be explored. With the various biomarkers that have either been recently discovered or are the subject of ongoing investigations, it is hoped that future trials would be designed to allow for studying targeted treatments in a biomarker-enriched population, which is defensible for the improvement of prognosis for SCLC and NSCLC patients. This review article sheds light on the different DNA repair pathways and some of the inhibitors targeting the proteins involved in the DNA damage response (DDR) machinery, such as ataxia telangiectasia and Rad3-related protein (ATR), DNA-dependent protein kinase (DNA-PK), and poly-ADP-ribose polymerase (PARP). In addition, the current status of DDR inhibitors in clinical settings and future perspectives are discussed.<\/jats:p>","DOI":"10.3390\/ph15121475","type":"journal-article","created":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T01:58:46Z","timestamp":1669600726000},"page":"1475","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Targeting the DNA Damage Response Machinery for Lung Cancer Treatment"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0680-1549","authenticated-orcid":false,"given":"Katharigatta N.","family":"Venugopala","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi Arabia"},{"name":"Department of Biotechnology and Food Science, Faculty of Applied Sciences, Durban University of Technology, Durban 4000, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Stefanou, D.T., Kouvela, M., Stellas, D., Voutetakis, K., Papadodima, O., Syrigos, K., and Souliotis, V.L. (2022). Oxidative Stress and Deregulated DNA Damage Response Network in Lung Cancer Patients. Biomedicines, 10.","DOI":"10.3390\/biomedicines10061248"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5334\/aogh.2419","article-title":"Global Epidemiology of Lung Cancer","volume":"85","author":"Barta","year":"2019","journal-title":"Ann. Glob. Health"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Souliotis, V.L., Vlachogiannis, N.I., Pappa, M., Argyriou, A., Ntouros, P.A., and Sfikakis, P.P. (2019). DNA Damage Response and Oxidative Stress in Systemic Autoimmunity. Int. J. Mol. Sci, 21.","DOI":"10.3390\/ijms21010055"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.cell.2017.01.002","article-title":"Review Endogenous DNA Damage as a Source of Genomic Instability in Cancer","volume":"168","author":"Edge","year":"2017","journal-title":"Cell"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.ctrv.2011.11.003","article-title":"De Targeted Agents in Non-Small Cell Lung Cancer (NSCLC ): Clinical Developments and Rationale for the Combination with Thoracic Radiotherapy","volume":"38","author":"Keng","year":"2012","journal-title":"Cancer Treat. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Reuvers, T.G.A., Kanaar, R., and Nonnekens, J. (2020). DNA Damage-Inducing Anticancer Therapies: From Global to Precision Damage. Cancers, 12.","DOI":"10.3390\/cancers12082098"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0209-3","article-title":"Extracellular Signal-Regulated Kinase 5 Increases Radioresistance of Lung Cancer Cells by Enhancing the DNA Damage Response","volume":"51","author":"Jiang","year":"2019","journal-title":"Exp. Mol. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00439-011-0983-z","article-title":"Integrative Computational Biology for Cancer Research","volume":"130","author":"Fortney","year":"2011","journal-title":"Hum. Genet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.lungcan.2010.08.022","article-title":"Lung Cancer Chemotherapy, Chemoresistance and the Changing Treatment Landscape for NSCLC","volume":"71","author":"Chang","year":"2011","journal-title":"Lung Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1007\/s11033-021-06314-z","article-title":"DNA Repair Pathways and Their Roles in Drug Resistance for Lung Adenocarcinoma Double Holliday Junction","volume":"48","author":"Kara","year":"2021","journal-title":"Mol. Biol. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1158\/1541-7786.MCR-18-0316","article-title":"Identification and Characterization of Oncogenic SOS1 Mutations in Lung Adenocarcinoma","volume":"17","author":"Cai","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nrc3342","article-title":"Genomic Instability in Cancer: The Effects of Deregulated DNA Damage Signalling on Cancer Chemotherapy Response and Resistance","volume":"12","author":"Bouwman","year":"2012","journal-title":"Nat. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"113458","DOI":"10.1016\/j.biopha.2022.113458","article-title":"Biomedicine & Pharmacotherapy PARP Inhibitors in Small Cell Lung Cancer: The Underlying Mechanisms and Clinical Implications","volume":"153","author":"Wang","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nrclinonc.2017.71","article-title":"Unravelling the Biology of SCLC: Implications for Therapy","volume":"14","author":"Sabari","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_15","first-page":"725","article-title":"Small-Cell Lung Cancer: What We Know, What We Need to Know and the Path Forward","volume":"17","author":"Gazdar","year":"2017","journal-title":"Nat. Publ. Gr."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.lungcan.2017.10.006","article-title":"Lung Cancer Targeting DNA Damage in SCLC","volume":"114","author":"Foy","year":"2017","journal-title":"Lung Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"6239","DOI":"10.1158\/1078-0432.CCR-17-1284","article-title":"Targeting AXL and MTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer","volume":"23","author":"Sen","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Cardnell, R.J., Feng, Y., Mukherjee, S., Diao, L., Tong, P., Stewart, A., Masrorpour, F., Fan, Y., Nilsson, M., and Shen, Y. (2016). Activation of the PI3K \/ MTOR Pathway Following PARP Inhibition in Small Cell Lung Cancer. PLoS ONE, 1.","DOI":"10.1371\/journal.pone.0152584"},{"key":"ref_19","first-page":"1","article-title":"Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer","volume":"19","author":"Cardnell","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_20","first-page":"798","article-title":"Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1","volume":"2","author":"Yordy","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1158\/0008-5472.CAN-16-3409","article-title":"CHK1 Inhibition in Small-Cell Lung Cancer Produces SingleAgent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib","volume":"77","author":"Sen","year":"2017","journal-title":"Cancer Res."},{"key":"ref_22","first-page":"620","article-title":"Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1\/2 Mutations and Selected Sporadic Cancers","volume":"7","author":"Ramanathan","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"50","DOI":"10.21037\/tlcr.2018.02.03","article-title":"Targeting DNA Damage Repair in Small Cell Lung Cancer and the Biomarker Landscape","volume":"7","author":"Sen","year":"2018","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/s41571-018-0008-0","article-title":"NewS & VIewS Opportunities and Challenges","volume":"15","author":"Kim","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_25","first-page":"1","article-title":"Small-Cell Lung Cancer Charles","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s40425-019-0690-1","article-title":"Immunotherapy in Small-Cell Lung Cancer: From Molecular Promises to Clinical Challenges","volume":"1","author":"Pavan","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.3390\/molecules27082491","article-title":"Recent Advances in Synergistic Antitumor Effects Exploited from the Inhibition of Ataxia Telangiectasia and RAD3-Related","volume":"27","author":"Atr","year":"2022","journal-title":"Molecules"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1091\/mbc.E15-10-0698","article-title":"Exploiting DNA Repair Defects for Novel Cancer Therapies","volume":"27","author":"Kanaar","year":"2016","journal-title":"Mol. Biol. Cell"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1158\/2159-8290.CD-16-0860","article-title":"Europe PMC Funders Group Targeting DNA Repair in Cancer: Beyond PARP Inhibitors","volume":"7","author":"Brown","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41401-020-00577-1","article-title":"Targeting DNA-PK Overcomes Acquired Resistance to Third-Generation EGFR-TKI Osimertinib in Non-Small-Cell Lung Cancer","volume":"42","author":"Liang","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1158\/1078-0432.CCR-14-2958","article-title":"Small Cell Lung Cancer: Will Recent Progress Lead to Improved","volume":"21","author":"Pietanza","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"100017","DOI":"10.1016\/j.crphar.2021.100017","article-title":"Current Research in Pharmacology and Drug Discovery Progress towards a Clinically-Successful ATR Inhibitor for Cancer Therapy","volume":"2","author":"Barnieh","year":"2021","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature14664","article-title":"Comprehensive genomic profiles of small cell lung cancer","volume":"524","author":"George","year":"2015","journal-title":"Nature"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1158\/1078-0432.CCR-16-1040","article-title":"PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer","volume":"23","author":"Lok","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_35","first-page":"1","article-title":"The Contribution of DNA Repair Pathways to Genome","volume":"fuac035","author":"Cook","year":"2022","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Sullivan, M.R., and Bernstein, K.A. (2018). RAD-ical New Insights into RAD51 Regulation. Genes, 9.","DOI":"10.20944\/preprints201811.0541.v1"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5295","DOI":"10.1038\/s41467-022-32743-w","article-title":"Multi-Pathway DNA-Repair Reporters Reveal Competition between End-Joining, Single-Strand Annealing and Homologous Recombination at Cas9-Induced DNA Double-Strand Breaks","volume":"13","author":"Kruswick","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"102869","DOI":"10.1016\/j.dnarep.2020.102869","article-title":"The MRE11 Complex: A Versatile Toolkit for the Repair of Broken DNA","volume":"91\u201392","author":"Reginato","year":"2020","journal-title":"DNA Repai"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1093\/nar\/gkv160","article-title":"Involvement of ATM in Homologous Recombination after End Resection and RAD51 Nucleofilament","volume":"43","author":"Borgmann","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/s41416-022-01900-9","article-title":"Discovery and Validation of a Transcriptional Signature Identifying Homologous Recombination-de Fi Cient Breast, Endometrial and Ovarian Cancers","volume":"127","author":"Beinse","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.bbrc.2019.11.050","article-title":"Biochemical and Biophysical Research Communications Non-Small Cell Lung Cancer Cells with de Fi Ciencies in Homologous Recombination Genes Are Sensitive to PARP Inhibitors","volume":"522","author":"Ji","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","article-title":"Mutational Landscape and Significance across 12 Major Cancer Types","volume":"502","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"ref_43","first-page":"PO.17.00286","article-title":"Prevalence of Homologous Recombination\u2014Related Gene Mutations Across Multiple Cancer Types Abstract","volume":"2018","author":"Pishvaian","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.celrep.2018.03.076","article-title":"Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas","volume":"23","author":"Knijnenburg","year":"2018","journal-title":"Cell Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41698-021-00199-8","article-title":"OPEN A Subset of Lung Cancer Cases Shows Robust Signs of Homologous Recombination de Fi Ciency Associated Genomic Mutational Signatures","volume":"5","author":"Diossy","year":"2021","journal-title":"NPJ Precis. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1128\/MCB.00847-15","article-title":"Role of Deubiquitinating Enzymes in DNA Repair","volume":"36","author":"Kee","year":"2016","journal-title":"Mol. Cell. Biol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"9830","DOI":"10.1074\/jbc.M116.763128","article-title":"The Deubiquitinating Enzyme Usp14 Allosterically Inhibits Multiple Proteasomal Activities and Ubiquitin-Independent Proteolysis","volume":"292","author":"Kim","year":"2017","journal-title":"J. Biol. Chem."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1093\/annonc\/mdr606","article-title":"Proteins Involved in DNA Damage Response Pathways and Survival of Stage I Non-Small-Cell Lung Cancer Patients","volume":"23","author":"Choi","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Yin, M., Liao, Z., Huang, Y., Liu, Z., Yuan, X., and Gomez, D. (2011). Polymorphisms of Homologous Recombination Genes and Clinical Outcomes of Non-Small Cell Lung Cancer Patients Treated with Definitive Radiotherapy. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0020055"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1158\/1078-0432.CCR-03-0372","article-title":"Polymorphisms in Genes Involved in Homologous Recombination Repair Interact to Increase the Risk of Developing Acute Myeloid Leukemia","volume":"10","author":"Seedhouse","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_51","first-page":"100068","article-title":"Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung Trial","volume":"1","author":"Remon","year":"2020","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"22429","DOI":"10.1073\/pnas.1916581116","article-title":"Epigenetic Targeting of DNA Repair in Lung Cancer","volume":"116","author":"Lok","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Sharma, A., and Almasan, A. (2020). USP14 Regulates DNA Damage Response and Is a Target for Radiosensitization in Non-Small Cell Lung Cancer. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21176383"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/s41388-021-01690-z","article-title":"CRL4A DTL Degrades DNA-PKcs to Modulate NHEJ Repair and Induce Genomic Instability and Subsequent Malignant Transformation","volume":"40","author":"Feng","year":"2021","journal-title":"Oncogene"},{"key":"ref_55","unstructured":"Chen, C. (2013). New Research Directions in DNA Repair\u2014Emerging Features of DNA Double-Strand Break Repair in Humans, IntechOpen. Chapter 7."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Yang, S., and Wang, X.Q. (2017). XLF-Mediated NHEJ Activity in Hepatocellular Carcinoma Therapy Resistance. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3345-y"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/cncr.26214","article-title":"Genetic Variants of the Nonhomologous End Joining Gene LIG4 and Severe Radiation Pneumonitis in Nonsmall Cell Lung Cancer Patients Treated with Definitive Radiotherapy","volume":"118","author":"Yin","year":"2012","journal-title":"Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Sishc, B.J., and Davis, A.J. (2017). The Role of the Core Non-Homologous End Joining Factors in Carcinogenesis and Cancer. Cancers, 9.","DOI":"10.3390\/cancers9070081"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.resinv.2018.11.005","article-title":"DNA repair as an emerging target for COPD-lung cancer overlap","volume":"57","author":"Sears","year":"2019","journal-title":"Respir. Investig."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1465-9921-9-12","article-title":"Diaphragm adaptations in patients with COPD","volume":"9","author":"Ottenheijm","year":"2008","journal-title":"Respir. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"6316","DOI":"10.3390\/ijms20246316","article-title":"Depletion of Akt1 and Akt2 Impairs the Repair of Radiation-Induced DNA Double Strand Breaks via Homologous Recombination","volume":"20","author":"Gol","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.radonc.2022.07.008","article-title":"Targeting HER3-Dependent Activation of Nuclear AKT Improves Radiotherapy of Non-Small Cell Lung Cancer","volume":"174","author":"Toulany","year":"2022","journal-title":"Radiother. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Weeden, C.E., Chen, Y., Ma, S.B., Hu, Y., Ramm, G., Sutherland, K.D., and Smyth, G.K. (2017). Lung Basal Stem Cells Rapidly Repair DNA Damage Using the Error-Prone Nonhomologous End-Joining Pathway. PLOS Biol., 15.","DOI":"10.1371\/journal.pbio.2000731"},{"key":"ref_64","first-page":"29","article-title":"Nucleosomes Regulate Base Excision Repair in Chromatin","volume":"780","author":"Meas","year":"2019","journal-title":"Mutat. Res. Mol. Mech. Mutagen."},{"key":"ref_65","first-page":"77","article-title":"Contributions of DNA Repair and Damage Response Pathways to the Non-Linear Genotoxic Responses of Alkylating Agents","volume":"767","author":"Klapacz","year":"2017","journal-title":"Mutat. Res. Mol. Mech. Mutagen."},{"key":"ref_66","first-page":"73","article-title":"Base Excision Repair and Cancer","volume":"327","author":"Manuscript","year":"2013","journal-title":"Cancer Lett."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1042\/EBC20200013","article-title":"Base Excision Repair and Its Implications to Cancer Therapy","volume":"64","author":"Grundy","year":"2020","journal-title":"Essays Biochem."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41419-019-1592-3","article-title":"SIRT1 Deacetylated and Stabilized XRCC1 to Promote Chemoresistance in Lung Cancer","volume":"10","author":"Yousafzai","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.lungcan.2021.03.006","article-title":"Lung Cancer Genomic Alterations and Clinical Outcomes in Patients with Lung Adenocarcinoma with Transformation to Small Cell Lung Cancer after Treatment with EGFR Tyrosine Kinase Inhibitors: A Multicenter Retrospective Study","volume":"155","author":"Wang","year":"2021","journal-title":"Lung Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Inhibitors, R.K. (2018). Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy. Cells, 7.","DOI":"10.3390\/cells7110212"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/0300060520927918","article-title":"Histological Transformation of Lung Adenocarcinoma to Small Cell Lung Cancer with Mutant C797S Conferring Acquired Resistance to Osimertinib","volume":"48","author":"Ren","year":"2020","journal-title":"J. Int. Med. Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.lungcan.2017.03.009","article-title":"A Phase Ib Trial of Continuous Once-Daily Oral Afatinib plus Sirolimus in Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer and\/or Disease Progression Following Prior Erlotinib or Gefitinib","volume":"108","author":"Insa","year":"2017","journal-title":"Lung Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"S454","DOI":"10.1016\/j.jtho.2018.08.546","article-title":"MA26.11 Effects of Dose Modifications on the Safety and Efficacy of Dacomitinib for EGFR Mutation-Positive NSCLC","volume":"13","author":"Mok","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.dnarep.2018.08.006","article-title":"Structural basis of DNA lesion recognition for eukaryotic transcription-coupled nucleotide excision repair","volume":"71","author":"Wang","year":"2018","journal-title":"DNA Repair"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"590242","DOI":"10.3389\/fcell.2020.590242","article-title":"Methods to Study Intracellular Movement and Localization of the Nucleotide Excision Repair Proteins at the DNA Lesions in Mammalian","volume":"8","author":"Shah","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Id, K.S., Id, D.A.P., Id, P.M., and Id, J.J.W. (2022). Set2 Histone Methyltransferase Regulates Transcription Coupled-Nucleotide Excision Repair in Yeast. PLoS Genet., 18.","DOI":"10.1371\/journal.pgen.1010085"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1080\/17425255.2018.1416095","article-title":"Pharmacogenetics of Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer: Predictive Validity of Polymorphisms of ERCC1","volume":"14","author":"Hamilton","year":"2018","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13000-019-0885-2","article-title":"Low ERCC1 Expression Is a Good Predictive Marker in Lung Adenocarcinoma Patients Receiving Chemotherapy Based on Platinum in All TNM Stages\u2014A Single-Center Study","volume":"14","author":"Pilji","year":"2019","journal-title":"Diagn. Pathol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"85","DOI":"10.33160\/yam.2019.03.012","article-title":"Effect of Cetuximab and EGFR Small Interfering RNA Combination Treatment in NSCLC Cell Lines with Wild Type EGFR and Use of KRAS as a Possible Biomarker for Treatment Responsiveness","volume":"62","author":"Miyake","year":"2019","journal-title":"Yonago Acta Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"102645","DOI":"10.1016\/j.pdpdt.2021.102645","article-title":"Photodiagnosis and Photodynamic Therapy Chlorin E6 Mediated Photodynamic Therapy Triggers Resistance through ATM-Related DNA Damage Response in Lung Cancer Cells","volume":"37","author":"Ma","year":"2022","journal-title":"Photodiagnosis Photodyn. Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s12032-022-01657-4","article-title":"Glioblastoma Recurrent Cells Switch between ATM and ATR Pathway as an Alternative Strategy to Survive Radiation Stress","volume":"39","author":"Kaur","year":"2022","journal-title":"Med. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Esposito, F., Giuffrida, R., Raciti, G., Puglisi, C., and Forte, S. (2021). Wee1 Kinase: A Potential Target to Overcome Tumor Resistance to Therapy. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221910689"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41420-022-01082-6","article-title":"An MTOR and DNA-PK Dual Inhibitor CC-115 Hinders Non-Small Cell Lung Cancer Cell Growth","volume":"8","author":"Chen","year":"2022","journal-title":"Cell Death Discov."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"828684","DOI":"10.3389\/fonc.2022.828684","article-title":"Targeting the DNA Damage Response for Cancer Therapy by Inhibiting the Kinase Wee1","volume":"12","author":"Bukhari","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s41392-022-01013-y","article-title":"Signal Pathways and Precision Therapy of Small-Cell Lung Cancer","volume":"7","author":"Yuan","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Knelson, E.H., and Patel, S.A. (2021). PARP Inhibitors in Small-Cell Lung Cancer: Rational Combinations to Improve Responses. Cancers, 13.","DOI":"10.3390\/cancers13040727"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.molcel.2020.07.026","article-title":"Review DNA Damage and Cancer Immunotherapy: A STING in the Tale","volume":"80","author":"Groelly","year":"2020","journal-title":"Mol. Cell"},{"key":"ref_88","first-page":"796","article-title":"Cellular Functions of the Protein Kinase ATM and Their Relevance to Human Disease","volume":"22","author":"Lee","year":"2021","journal-title":"Mol. Cell Biol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1080\/10715762.2021.1876853","article-title":"Activation of DNA Damage Response Signaling in Mammalian Cells by Ionizing Radiation","volume":"55","author":"Ghosh","year":"2021","journal-title":"Free Radic. Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.gde.2021.07.003","article-title":"ScienceDirect An Extending ATR\u2013CHK1 Circuitry: The Replication Stress Response and Beyond","volume":"71","author":"Simoneau","year":"2021","journal-title":"Curr. Opin. Genet. Dev."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ccell.2021.02.014","article-title":"Article Therapeutic Targeting of ATR Yields Durable Regressions in Small Cell Lung Cancers with High Replication Stress Therapeutic Targeting of ATR Yields Durable Regressions in Small Cell Lung Cancers with High Replication Stress","volume":"39","author":"Rajapakse","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nrm.2016.111","article-title":"Roles of Eukaryotic Topoisomerases in Transcription, Replication and Genomic Stability","volume":"17","author":"Pommier","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.radonc.2017.06.025","article-title":"Inhibition of Ataxia Telangiectasia Related-3 ( ATR ) Improves Therapeutic Index in Preclinical Models of Non-Small Cell Lung Cancer ( NSCLC ) Radiotherapy","volume":"124","author":"Dunne","year":"2017","journal-title":"Radiother. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1200\/JCO.2017.76.6915","article-title":"Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors","volume":"36","author":"Thomas","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1158\/1535-7163.MCT-20-1026","article-title":"Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging Agents","volume":"20","author":"Jo","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Hur, J., Ghosh, M., Kim, T.H., Park, N., Pandey, K., Cho, Y.B., Hong, S.D., Katuwal, N.B., Kang, M., and An, H.J. (2021). Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22031223"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1158\/1541-7786.MCR-20-0414","article-title":"AXL Inhibition Induces DNA Damage and Replication Stress in Non-Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors","volume":"19","author":"Ramkumar","year":"2021","journal-title":"Mol. Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"18882","DOI":"10.1038\/s41598-019-54796-6","article-title":"Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models","volume":"9","author":"Wis","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/cmdc.201700143","article-title":"Targeting DNA-Dependent Protein Kinase for Cancer Therapy","volume":"2017","author":"Harnor","year":"2017","journal-title":"ChemMedChem"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1158\/1535-7163.MCT-17-1267","article-title":"The DNA-PK Inhibitor VX-984 Enhances the Radiosensitivity of Glioblastoma Cells Grown In Vitro and as Orthotopic Xenografts","volume":"17","author":"Timme","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1158\/1535-7163.MCT-19-0734","article-title":"Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models","volume":"19","author":"Zenke","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3389\/fonc.2020.00127","article-title":"DNA-PK Inhibitor, M3814, as a New Combination Partner of Mylotarg in the Treatment of Acute Myeloid Leukemia","volume":"10","author":"Carr","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_103","first-page":"280","article-title":"ORIGINAL ARTICLE A Potentially Functional Polymorphism in ABCG2 Predicts Clinical Outcome of Non-Small Cell Lung Cancer in a Chinese Population","volume":"17","author":"Sun","year":"2017","journal-title":"Pharm. J."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"674","DOI":"10.3389\/fonc.2020.00674","article-title":"M3814, a DNA-PK Inhibitor, Modulates ABCG2-Mediated Multidrug Resistance in Lung Cancer","volume":"10","author":"Zou","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/0284186X.2017.1404634","article-title":"A Systematic Review of Targeted Agents for Non-Small Cell Lung Cancer","volume":"57","author":"Vestergaard","year":"2018","journal-title":"Acta Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bcp.2014.05.011","article-title":"Targeting PI3K \/ AKT \/ MTOR Pathway in Non Small Cell Lung Cancer","volume":"90","author":"Fumarola","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/1759-7714.13328","article-title":"Targeting the PI3K \/ Akt \/ MTOR Pathway in Non-Small Cell Lung Cancer ( NSCLC )","volume":"11","author":"Tan","year":"2020","journal-title":"Thorac. Cancer"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"20445","DOI":"10.18632\/aging.103847","article-title":"Dual Inhibition of DNA-PKcs and MTOR by CC-115 Potently Inhibits Human Renal Cell Carcinoma Cell Growth","volume":"12","author":"Zheng","year":"2020","journal-title":"Aging"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"B\u00fcrkel, F., Jost, T., Hecht, M., Heinzerling, L., Fietkau, R., and Distel, L. (2020). Dual MTOR\/DNA-PK Inhibitor CC-115 Induces Cell Death in Melanoma Cells and Has Radiosensitizing Potential. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21239321"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"10463","DOI":"10.2147\/CMAR.S208720","article-title":"First-In-Human Phase I Study Of A Dual MTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy","volume":"11","author":"Munster","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"74688","DOI":"10.18632\/oncotarget.20342","article-title":"CC-115, a Dual Inhibitor of MTOR Kinase and DNA-PK, Blocks DNA Damage Repair Pathways and Selectively Inhibits ATM-Deficient Cell Growth in Vitro","volume":"8","author":"Tsuji","year":"2017","journal-title":"Oncotarget"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1016\/j.apsb.2021.07.029","article-title":"DNA-PK Inhibition by M3814 Enhances Chemosensitivity in Non-Small Cell Lung Cancer","volume":"11","author":"Wang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3892\/mco.2021.2369","article-title":"Expression of Immune Checkpoint PD-1 in Non-Small Cell Lung Cancer Is Associated with Tumor Cell DNA\u2014Dependent Protein Kinase","volume":"15","author":"Saar","year":"2021","journal-title":"Mol. Clin. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/s41571-018-0055-6","article-title":"Synthetic lethal therapies for cancer: What\u2019s next after PARP inhibitors?","volume":"15","author":"Ashworth","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1126\/science.abb4542","article-title":"Europe PMC Funders Group Targeting the Nucleotide Salvage Factor DNPH1 Sensitizes BRCA\u2014Deficient Cells to PARP Inhibitors","volume":"372","author":"Fugger","year":"2021","journal-title":"Science"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1800654","DOI":"10.1002\/advs.201800654","article-title":"Circular RNA CircNOL10 Inhibits Lung Cancer Development by Promoting SCLM1-Mediated Transcriptional Regulation of the Humanin Polypeptide Family","volume":"6","author":"Nan","year":"2019","journal-title":"Adv. Sci."},{"key":"ref_117","first-page":"188552","article-title":"BBA\u2014Reviews on Cancer Role of MicroRNAs in Regulating Cell Proliferation, Metastasis and Chemoresistance and Their Applications as Cancer Biomarkers in Small Cell Lung Cancer","volume":"1876","author":"Pandey","year":"2021","journal-title":"BBA Rev. Cancer"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"505","DOI":"10.3322\/caac.21630","article-title":"An Update on the Immune Landscape in Lung and Head and Neck Cancers","volume":"70","author":"Carlisle","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.tips.2019.03.005","article-title":"Unexpected Synergy Reveals New Therapeutic Strategy in SCLC","volume":"40","author":"Drapkin","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_120","first-page":"130","article-title":"Profiling of DNA damage and repair pathways in small cell lung cancer reveals a suppressive role in the immune landscape. Mol","volume":"20","author":"Jin","year":"2021","journal-title":"Cancer"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1200\/JCO.18.00264","article-title":"Original Report Abstract Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study","volume":"37","author":"Owonikoko","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1158\/2159-8290.CD-19-0582","article-title":"Combination Olaparib and Temozolomide in Relapsed Small Cell Lung Cancer","volume":"9","author":"Farago","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_123","first-page":"5143","article-title":"Talazoparib Is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts","volume":"24","author":"Lines","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1126\/science.aak9654","article-title":"DNA-PKcs Structure Suggests an Allosteric Mechanism Modulating DNA Double-Strand Break Repair","volume":"194","author":"Sibanda","year":"2017","journal-title":"Science"},{"key":"ref_125","first-page":"1104","article-title":"Integrative Genome Analyses Identify Key Somatic Driver Mutations of Small Cell Lung Cancer","volume":"44","author":"Genet","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_126","first-page":"646","article-title":"Targeting DNA Damage Response Promotes Anti-Tumor Immunity through STING-Mediated T-Cell Activation in Small Cell Lung Cancer","volume":"9","author":"Fujimoto","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1158\/1078-0432.CCR-11-2059","article-title":"Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential Biomarker","volume":"18","author":"Pietanza","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_128","first-page":"222","article-title":"PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors","volume":"16","author":"Reichert","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"210079","DOI":"10.1183\/16000617.0079-2021","article-title":"Recent developments in the treatment of small cell lung cancer","volume":"30","author":"Hiddinga","year":"2021","journal-title":"Eur. Respir. Rev."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/12\/1475\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:27:43Z","timestamp":1760146063000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/12\/1475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,27]]},"references-count":129,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["ph15121475"],"URL":"https:\/\/doi.org\/10.3390\/ph15121475","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,27]]}}}